Overview

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Status:
Not yet recruiting

Trial end date:
2026-04-30

Target enrollment:

Participant gender:

Summary

Based on preclinical data, the investigators hypothesize that IRAK4 inhibition cripples tumor-intrinsic survival signaling and effectively overcomes the desmoplastic and immune-suppressive TME to render chemo- and immunotherapies effective in gastrointestinal (GI) malignancy. Therefore, this trial is designed to evaluate combination of CA-4948 and standard chemo/immunotherapy in untreated gastric and esophageal cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Washington University School of Medicine

Collaborator:

Curis, Inc.

Treatments:

Leucovorin
Nivolumab
Oxaliplatin
Pembrolizumab
Trastuzumab